One world, many inequalities
Haemophilia and allied bleeding disorders are treatable with proper diagnosis and care. People can lead normal lives and have a near-normal life expectancy.
Unfortunately, that’s not the case for all people with haemophilia, particularly in developing and emerging countries where many remain undiagnosed or lack adequate care.
One standard the world over
Realising the vast disparity between
standards of care around the world, Novo Nordisk, a global Danish
pharmaceutical company, established the Novo Nordisk Haemophilia Foundation
(NNHF) to improve care for people with haemophilia in developing and emerging
NNHF reflects Novo Nordisk’s commitment to corporate social responsibility.